John M. Capek, Executive Vice President at ABBOTT LABORATORIES (ABT), sold 38,773 shares at $45.82 ($1.8M) on 2015-02-04, disclosed to the SEC on 2015-02-06.
Scheduled sale ($1.8M) by Executive Vice President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.72 | 2,300 | $105K | 5.9% |
| 2 | $45.72 | 800 | $37K | 2.1% |
| 3 | $45.72 | 100 | $5K | 0.3% |
| 4 | $45.73 | 5,000 | $229K | 12.9% |
| 5 | $45.73 | 100 | $5K | 0.3% |
| 6 | $45.73 | 1,300 |
| $59K |
| 3.4% |
| 7 | $45.74 | 2,900 | $133K | 7.5% |
| 8 | $45.74 | 700 | $32K | 1.8% |
| 9 | $45.75 | 300 | $14K | 0.8% |
| 10 | $45.75 | 900 | $41K | 2.3% |
| 11 | $45.76 | 400 | $18K | 1.0% |
| 12 | $45.76 | 1,384 | $63K | 3.6% |
| 13 | $45.76 | 200 | $9K | 0.5% |
| 14 | $45.77 | 100 | $5K | 0.3% |
| 15 | $45.77 | 3,016 | $138K | 7.8% |
| 16 | $45.77 | 4,000 | $183K | 10.3% |
| 17 | $45.78 | 100 | $5K | 0.3% |
| 18 | $45.78 | 2,400 | $110K | 6.2% |
| 19 | $45.78 | 1,600 | $73K | 4.1% |
| 20 | $45.79 | 400 | $18K | 1.0% |
| 21 | $45.79 | 1,100 | $50K | 2.8% |
| 22 | $45.79 | 200 | $9K | 0.5% |
| 23 | $45.80 | 1,800 | $82K | 4.6% |
| 24 | $45.80 | 1,373 | $63K | 3.5% |
| 25 | $45.80 | 100 | $5K | 0.3% |
| 26 | $45.81 | 900 | $41K | 2.3% |
| 27 | $45.81 | 400 | $18K | 1.0% |
| 28 | $45.81 | 4,300 | $197K | 11.1% |
| 29 | $45.82 | 100 | $5K | 0.3% |
| 30 | $45.82 | 500 | $23K | 1.3% |
| Total | $45.77 avg | 38,773 | $1.8M | 100% |
| Filing → |
| ABT | SELL | 2020-04-23 | $9.6M | — | Filing → |
| ABT | SELL | 2019-06-21 | $4.0M | — | Filing → |
| ABT | SELL | 2018-07-26 | $4.2M | — | Filing → |